USPTO 2015–2025 USPTO PatentsView US Corporation

Accelerate Diagnostics, Inc.

USPTO PatentsView assignee record - 20 granted patents across 12 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).

RSS updates for this company

The verdict

According to USPTO PatentsView, Accelerate ranks #14,421 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 12 technology areas.

#14,421
of 49,997 US assignees by volume
40th percentile
by Innovation Score (32.2/100)
13.3
avg claims per patent
-46%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R14421 · US Corporation #14,421 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-SMALL 20 grants
  • MID-PACK #14,421/49,997
  • PHOTO-FINISH Aalto University
  • CPC-FOCUS G01N · 12 areas
  • INNOV-THIN 32.2/100
  • CLAIMS-RICH 13.3 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -46% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aalto University (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Accelerate’s 32.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Accelerate

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Accelerate's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Accelerate?

Each dot is one of Accelerate’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Accelerate’s own 13.3 claims/patent is at or below the 17.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Accelerate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 19.919.92020.1 1015202530 Granted patents (volume) Avg claims / patent Aveo Pharmaceuticals, Inc. - 20, 19.4Aveo Pharmaceutic…Aalto University - 20, 15.75Aalto UniversityAbbott Laboratories Vascular Enterprises Limited - 20, 17.15Abbott Laboratori…Abyrx, Inc. - 20, 18.95AbyrxAccutar Biotechnology Inc. - 20, 24.5Accutar Biotechno…Aclaris Therapeutics, Inc. - 20, 25.75Aclaris Therapeut…Actimize Ltd. - 20, 15.85ActimizeActionPower Corp. - 20, 12.55ActionpowerAccelerate Diagnostics, Inc. - 20, 13.25Accelerate Diagno…
Accelerate vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Accelerate's grants concentrate

Accelerate Diagnostics, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 80% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2017 (5 grants) versus a trough of 1 in 2018. By volume, Accelerate sits between Aveo Pharmaceuticals, Inc. and ActionPower Corp..

Accelerate's three-year grant acceleration

Accelerate Diagnostics, Inc. shows 2 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Accelerate's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Accelerate holds 20 patents at rank #14,446, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Accelerate

By rank, the assignees closest to #14,446 in granted patent volume.

Leaders in G01N (Investigating OR Analysing Materials BY Determining Their…)

Other assignees with the most granted patents in Accelerate's primary technology class.

Accelerate's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 20162017201820192020202120232024 1
USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Accelerate Diagnostics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 3 15.0%
2017 5 25.0%
2018 1 5.0%
2019 4 20.0%
2020 2 10.0%
2021 3 15.0%
2023 1 5.0%
2024 1 5.0%

Which technologies does Accelerate Diagnostics, Inc. patent most?

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Accelerate Diagnostics, Inc.'s patent record in context - here's where to go next.

  • Accelerate Diagnostics, Inc.'s lead technology class is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties), 80% of its portfolio - see every assignee active in that class. Explore G01N
  • Ranked #14,421 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Accelerate Diagnostics, Inc. against Aveo Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 32.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.